Publications

5600 Results

Nut consumption and survival in stage III colon cancer patients: results from CALGB 89803 (Alliance)

Authors
T Fadelu;D Niedzwiecki;S Zhang;X Ye;L Saltz;R Mayer;R Mowat;R Whittom;A Hantel;A Benson;D Atienza;M Messino;H Kindler;A Venook;S Ogino;K Ng;E Giovannucci;J Meyerhardt;Y Bao;C Fuchs
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3517); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
C89803

Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance)

Authors
F Sinicrope;Q Shi;T Smyrk;R Goldberg;W Heying;E Chan;S Gill;M Kahlenberg;S Nair;A Shields;D Sargent;M Pollak;S Alberts
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3516); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/N0147

Association of immune markers and immunoscore with survival of stage III colon cancer (CC) patients treated with adjuvant FOLFOX: NCCTG N0147 (Alliance)

Authors
F Sinicrope;Q Shi;F Hermitte;E Heying;E Chan;S Gill;R Goldberg;M Kahlenberg;S Nair;A Shields;D Sargent;J Galon;S Alberts
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3579); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/N0147

Genetic correlates of therapeutic toxicities of stage III colon cancer patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance)

Authors
P Newcomb;M Sun;X Hua;B Banbury;A Phipps;J Kocarnik;T Harrison;Q Shi;F Sinicrope;S Thidbodeau;E Chan;S Gill;R Goldberg;M Kahlenberg;S Nair;A Shields;U Peters;S Alberts;AT Chan
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3604); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/N0147

Adjuvant androgen deprivation (AD) +mitoxantrone + prednisone (MP) in high risk prostate cancer (PC) patients post radical prostatectomy (RP): phase III intergroup trial S9921

Authors
M Hussain;C Tangen;IM Thompson;G Swanson;DP Wood;W Sakr;NA Dawson;NB Haas;TW Flaig;T Dorff;D Lin;ED Crawford;DI Quinn;N Vogelzang;LM Glode
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 5019); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion
Year
2017
Research Committee(s)
Genitourinary
Study Number(s)
S9921

Everolimus (EVE) exposure as a predictor of toxicity in renal cell cancer (RCC) patients (pts) in the adjuvant setting: results of pharmacokinetic analysis initial results for from SWOG S0931 (EVEREST), a phase III study (ClinicalTrials.gov Identifier:NCT01120249).

Authors
T Synold;M Plets;C Tangen;E Heath;G Palapattu;PC Mack;MN Stein;MV Meng;NJ Vogelzang;IM Thompson;C Ryan
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 4566); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Genitourinary
Study Number(s)
S0931

A phase 3 randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC, EA8143)

Authors
LC Harshman;M Puligandla;N Haas;M Allaf;D McDermott;S Signoretti;R Gupta;TK Choueiri;P Lara;A Kapoor;D Heng;B Shuch;M Jewett;D George;D Michaelson;R Bhat;E Van Allen;V Master;MA Carducci
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr TPS4596);American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster session (TIP)
Year
2017
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/EA8143

A randomized, phase II efficacy assessment of multiple MET kinase inhibitors (Cabozantinib [NSC #761968], crizotinib [NSC #749005], savolitinib [NSC #785348], and sunitinib [NSC #736511]) in metastatic papillary renal carcinoma (PAPMET): SWOG S1500, NCT02761057

Authors
S Pal;C Tangen;IM Thompson;B Shuch;N Balzer-Haas;DJ George;M Stein;M Plets;P Lara
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr TPS4599); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Genitourinary
Study Number(s)
S1500

SWOG S1605: phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer

Authors
P Singh;C Tangen;SP Lerner;D McConkey;M Plets;MS Lucia;ME Woods;T Bivilacqua;W Kassouf;R Bangs;IM Thompson;P Black
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr TPS4591); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Genitourinary
Study Number(s)
S1605

S1605: phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer

Authors
P Singh;SP Lerner;D McConkey;MS Lucia;W Kassouf;ME Woods;T Bivilacqua;M Plets;C Tangen;P Black
Journal / Conference
Canadian Urological Association Journal June Vol 11(6Suppl4): abst. MP-04.15; Canadian Urological Association annual meeting (June 24-27, 2017, Toronto, Ontario, Canada), poster
Year
2017
Research Committee(s)
Genitourinary
Study Number(s)
S1605